Orchid Pharma Ltd.
Fundamentals
- Market cap
- ₹4,886 cr
- P/E
- 237.79×
- ROE
- 7.86%
- Debt / equity
- 0.14
- 52-week range
- 480.00 — 1094.00
Orchid Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 7 notes on Orchid Pharma Ltd.
June 2026
- 05 Jun 26 · 5:30 PM IST Lead Lead · M&A · Small cap
NCLT clears Orchid-Dhanuka merger. Integration starts now.
The Chennai bench approved the scheme on Friday, turning a March announcement into an executable deal. The order copy is awaited.
- 01 Jun 26 · 6:44 PM IST Brief Brief · Earnings · Small cap
Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
Out-licensing talks for the antibiotic are at an advanced stage in multiple regions. Management also outlined a new $1.2 billion US market initiative.
May 2026
- 26 May 26 · 5:51 PM IST Brief Brief · Concalls · Small cap
Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion
Management now expects peak revenue for its key antibiotic to hit $1-2 billion. A long-awaited out-licensing deal remains unsigned.
- 25 May 26 · 9:14 PM IST Brief Brief · Earnings · Small cap
Orchid Pharma annual profit drops to ₹45.2 crore
The company reported a sharp decline in annual standalone profit as auditors flagged unaudited US subsidiaries in the consolidated results.
- 25 May 26 · 8:00 PM IST Brief Brief · Earnings · Small cap
Orchid Pharma profit falls 57% on higher costs; auditor flags US units
Standalone net profit for FY26 dropped to ₹45.2 crore from ₹106.5 crore, confirming a severe earnings slide first signaled in Q3.
- 25 May 26 · 7:38 PM IST Brief Brief · Earnings · Small cap
Orchid Pharma's annual profit drops 57%, auditor flags US subsidiary issues
Full-year profit fell to ₹45.2 crore from ₹106.5 crore a year ago. The auditor gave a qualified opinion on consolidated accounts due to unaudited US subsidiaries.